xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
|
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
来源
CANCER MEDICINE | 2024年 / 13卷 / 21期
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Risk factors for cervical lymph node metastasis of head and neck squamous cell carcinoma: A retrospective population-based study
    Zhang, Yamin
    Yu, Jing
    Zhu, Huiyong
    JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY, 2022, 123 (05) : E484 - E488
  • [32] Head and Neck Cutaneous Squamous Cell Carcinoma Clinicopathological Risk Factors according to Age and Gender: A Population-based Study
    Wiser, Itay
    Scope, Alon
    Azriel, David
    Zloczower, Elhanan
    Carmel, Narin N.
    Shalom, Avshalom
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (05): : 275 - 278
  • [33] Perioperative Survival of Elderly Head and Neck Squamous Cell Carcinoma Patients
    Stokes, William A.
    Fuller, Collin
    Day, Terry A.
    Gillespie, Marion B.
    LARYNGOSCOPE, 2014, 124 (10): : 2281 - 2286
  • [34] Survival Outcomes for Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
    Sullivan, Christopher Blake
    Andresen, Nicholas S.
    Kendell, Nicholas
    Al-Qurayshi, Zaid
    Pagedar, Nitin A.
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2019, 128 (10): : 949 - 955
  • [35] A New Approach to Survival Analysis of Head and Neck Squamous Cell Carcinoma
    Masoudi, Sahar
    Montazeri, Seyed Ali
    Pourdanesh, Fereydoun
    Biglarian, Akbar
    Kazemi, Masoud
    Rahgozar, Mehdi
    ARCHIVES OF IRANIAN MEDICINE, 2017, 20 (08) : 503 - 510
  • [36] Distant Metastases and Survival Prediction in Head and Neck Squamous Cell Carcinoma
    Lee, Dong Hwan
    Kim, Min Joo
    Roh, Jong-Lyel
    Kim, Sung-Bae
    Choi, Seung-Ho
    Nam, Soon Yuhl
    Kim, Sang Yoon
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2012, 147 (05) : 870 - 875
  • [37] The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck
    Hall, SF
    Groome, PA
    Rothwell, D
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2000, 22 (04): : 317 - 322
  • [38] Racial differences in stage and survival in head and neck squamous cell carcinoma
    Nichols, Anthony C.
    Bhattacharyya, Neil
    LARYNGOSCOPE, 2007, 117 (05): : 770 - 775
  • [39] A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly
    Bhattacharyya, N
    LARYNGOSCOPE, 2003, 113 (02): : 368 - 372
  • [40] Poor Survival for American Indians with Head and Neck Squamous Cell Carcinoma
    Dwojak, Sunshine M.
    Finkelstein, Dianne M.
    Emerick, Kevin S.
    Lee, John H.
    Petereit, Daniel G.
    Deschler, Daniel G.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2014, 151 (02) : 265 - 271